MIRA Pharmaceuticals’ oral ketamine analog, Ketamir-2, has demonstrated significant potential in reversing neuropathic pain in a recent preclinical study. The drug showed superior efficacy compared to traditional oral ketamine, achieving complete normalization of pain thresholds in rats. MIRA is optimistic about the potential of Ketamir-2 for treating neuropathic pain and cancer-induced depression, with human trials potentially starting as early as 2025.